Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma
Phase of Trial: Phase 0
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 25 Jul 2019 Planned End Date changed from 15 Apr 2021 to 15 Apr 2022.
- 25 Jul 2019 Planned primary completion date changed from 15 Apr 2019 to 15 Apr 2020.
- 16 May 2018 Status changed from not yet recruiting to recruiting.